Dave Fellows

Mr. Fellows has more than 25 years of industry experience and currently serves on the board of Jaguar Gene Therapy, Axovia Therapeutics and the Glaucoma Foundation, and as the chairman of the board for Oxular Limited. He was previously on the board of Gyroscope Therapeutics and Arctos Medical. Mr. Fellows was most recently the Chief Executive Officer of Nightstar Therapeutics, a retinal gene therapy company acquired by Biogen in 2019. Prior to joining Nightstar Therapeutics, he was the Vice President of Johnson & Johnson’s Vision Care Franchise where he led global marketing, new product and licensing activities. Before joining Johnson & Johnson, he held leadership positions at Allergan, Inc. for 25 years where he served primarily in the sales and marketing areas in a number of capacities, including Regional President, Corporate Vice President, and Senior Vice President across North America, Europe and Asia. David holds a B.A. in Psychology from Butler University.